Herve Puy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8790272/publications.pdf

Version: 2024-02-01

148 papers	7,484 citations	61984 43 h-index	60623 81 g-index
157 all docs	157 docs citations	157 times ranked	6691 citing authors

#	Article	IF	Citations
1	Givosiran in acute intermittent porphyria: A personalized medicine approach. Molecular Genetics and Metabolism, 2022, 135, 206-214.	1.1	17
2	Crosstalk between Acidosis and Iron Metabolism: Data from In Vivo Studies. Metabolites, 2022, 12, 89.	2.9	1
3	Towards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases. Nutrients, 2022, 14, 1039.	4.1	11
4	Phlebotomy as an efficient long-term treatment of congenital erythropoietic porphyria. Haematologica, 2021, 106, 913-917.	3.5	13
5	A mutation in the iron-responsive element of <i>ALAS2</i> is a modifier of disease severity in a patient suffering from <i>CLPX</i> associated erythropoietic protoporphyria. Haematologica, 2021, 106, 2030-2033.	3.5	10
6	Identification of novel UROS mutations in a patient with congenital erythropoietic porphyria and efficient treatment by phlebotomy. Molecular Genetics and Metabolism Reports, 2021, 27, 100722.	1.1	5
7	Hepcidin and Iron Deficiency in Women One Year after Sleeve Gastrectomy: A Prospective Cohort Study. Nutrients, 2021, 13, 2516.	4.1	4
8	Analytical comparison of ELISA and mass spectrometry for quantification of serum hepcidin in critically ill patients. Bioanalysis, 2021, 13, 1029-1035.	1.5	6
9	Renal Function Decline Under Therapy With Small Interfering RNA Silencing ALAS1 for Acute Intermittent Porphyria. Kidney International Reports, 2021, 6, 1904-1911.	0.8	24
10	ABCB6 Polymorphisms are not Overly Represented in Patients with Porphyria. Blood Advances, 2021, , .	5.2	2
11	Iron, Heme Synthesis and Erythropoietic Porphyrias: A Complex Interplay. Metabolites, 2021, 11, 798.	2.9	11
12	TSPO2 translocates 5â€aminolevulinic acid into human erythroleukemia cells. Biology of the Cell, 2020, 112, 113-126.	2.0	3
13	Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria. Blood, 2020, 136, 2457-2468.	1.4	16
14	Kidney transplantation improves the clinical outcomes of Acute Intermittent Porphyria. Molecular Genetics and Metabolism, 2020, 131, 259-266.	1.1	7
15	Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. Molecular Genetics and Metabolism, 2019, 128, 309-313.	1.1	9
16	A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome. Science Translational Medicine, 2019, 11, .	12.4	55
17	Genetic background influences hepcidin response to iron imbalance in a mouse model of hemolytic anemia (Congenital erythropoietic porphyria). Biochemical and Biophysical Research Communications, 2019, 520, 297-303.	2.1	7
18	GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase in Human congenital sideroblastic anemia. Molecular Genetics and Metabolism, 2019, 128, 342-351.	1.1	19

#	Article	IF	Citations
19	Erythroid-Progenitor-Targeted Gene Therapy Using Bifunctional TFR1 Ligand-Peptides in Human Erythropoietic Protoporphyria. American Journal of Human Genetics, 2019, 104, 341-347.	6.2	22
20	Regulation of globin-heme balance in Diamond-Blackfan anemia by HSP70/GATA1. Blood, 2019, 133, 1358-1370.	1.4	44
21	International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias. Genetics in Medicine, 2019, 21, 2605-2613.	2.4	16
22	Regulation and tissue-specific expression of Î´-aminolevulinic acid synthases in non-syndromic sideroblastic anemias and porphyrias. Molecular Genetics and Metabolism, 2019, 128, 190-197.	1.1	25
23	Functional erythropoietinâ€hepcidin axis in recombinant human erythropoietin independent haemodialysis patients. Nephrology, 2019, 24, 751-757.	1.6	4
24	Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword. Molecular Genetics and Metabolism, 2019, 128, 236-241.	1.1	32
25	Systemic Administered mRNA as Therapy for Metabolic Diseases. Trends in Molecular Medicine, 2019, 25, 3-5.	6.7	4
26	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. Haematologica, 2019, 104, 497-504.	3.5	17
27	Extrahepatic hepcidin production: The intriguing outcomes of recent years. World Journal of Clinical Cases, 2019, 7, 1926-1936.	0.8	11
28	Porphyria and kidney diseases. CKJ: Clinical Kidney Journal, 2018, 11, 191-197.	2.9	43
29	Gene Therapy in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2018, 378, 1479-1493.	27.0	525
30	From a dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent porphyria. Human Molecular Genetics, 2018, 27, 1164-1173.	2.9	73
31	Urinary metabolic profiling of asymptomatic acute intermittent porphyria using a rule-mining-based algorithm. Metabolomics, 2018, 14, 10.	3.0	7
32	Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease. Haematologica, 2018, 103, 587-596.	3.5	18
33	Iron deficiency diagnosed using hepcidin on critical care discharge is an independent risk factor for death and poor quality of life at one year: an observational prospective study on 1161 patients. Critical Care, 2018, 22, 314.	5.8	39
34	Characterization and origin of heme precursors in amniotic fluid: lessons from normal and pathological pregnancies. Pediatric Research, 2018, 84, 80-84.	2.3	1
35	High urinary ferritin reflects myoglobin iron evacuation in DMD patients. Neuromuscular Disorders, 2018, 28, 564-571.	0.6	13
36	Gene Therapy in a Patient with Sickle Cell Disease. New England Journal of Medicine, 2017, 376, 848-855.	27.0	567

#	Article	IF	Citations
37	Hemolytic anemia repressed hepcidin level without hepatocyte iron overload: lesson from GÃ¼nther disease model. Haematologica, 2017, 102, 260-270.	3.5	13
38	Acute hepatic and erythropoietic porphyrias: from ALA synthases 1 and 2 to new molecular bases and treatments. Current Opinion in Hematology, 2017, 24, 198-207.	2.5	23
39	Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early inâ€hospital phase and 30â€day followâ€up. European Journal of Heart Failure, 2017, 19, 1075-1076.	7.1	37
40	Iloprost Use in Patients with Persistent Intestinal Ischemia Unsuitable for Revascularization. Annals of Vascular Surgery, 2017, 42, 128-135.	0.9	6
41	Isoniazid inhibits human erythroid 5-aminolevulinate synthase: Molecular mechanism and tolerance study with four X-linked protoporphyria patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 428-439.	3.8	12
42	A Variant of Peptide Transporter 2 Predicts the Severity of Porphyria-Associated Kidney Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 1924-1932.	6.1	46
43	Impact of iron deficiency diagnosis using hepcidin mass spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: Study protocol for a multicentre, randomised, single-blinded medico-economic trial. Anaesthesia, Critical Care & Pain Medicine, 2017, 36, 391-396.	1.4	9
44	Mutation in human CLPX elevates levels of Î´- aminolevulinate synthase and protoporphyrin IX to promote erythropoietic protoporphyria. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8045-E8052.	7.1	69
45	GNPAT polymorphism rs11558492 is not associated with increased severity in a large cohort of HFE p.Cys282Tyr homozygous patients. Hepatology, 2017, 65, 1069-1071.	7.3	4
46	Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clinical Chemistry and Laboratory Medicine, 2017, 55, 474-483.	2.3	70
47	Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome. PLoS ONE, 2017, 12, e0172147.	2.5	44
48	Does IV Iron Induce Plasma Oxidative Stress in Critically Ill Patients? A Comparison With Healthy Volunteers*. Critical Care Medicine, 2016, 44, 521-530.	0.9	13
49	Reply. Gastroenterology, 2016, 151, 771-772.	1.3	2
50	Heterozygous Mutations in BMP6 Pro-peptide Lead to Inappropriate Hepcidin Synthesis and Moderate Iron Overload in Humans. Gastroenterology, 2016, 150, 672-683.e4.	1.3	73
51	Hepcidin as a Major Component of Renal Antibacterial Defenses against Uropathogenic Escherichia coli. Journal of the American Society of Nephrology: JASN, 2016, 27, 835-846.	6.1	42
52	Update from the Hgb-205 Phase 1/2 Clinical Study of Lentiglobin Gene Therapy: Sustained Clinical Benefit in Severe Hemoglobinopathies. Blood, 2016, 128, 2311-2311.	1.4	4
53	A Dominant Mutation in Mitochondrial Unfoldase CLPX Results in Erythropoietic Protoporphyria. Blood, 2016, 128, 77-77.	1.4	0
54	Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites. Blood, 2015, 125, 534-541.	1.4	37

#	Article	IF	Citations
55	Iron Regulatory Protein 1 Sustains Mitochondrial Iron Loading and Function in Frataxin Deficiency. Cell Metabolism, 2015, 21, 311-323.	16.2	61
56	Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. Journal of Hepatology, 2015, 62, 848-854.	3.7	228
57	Porphyrias: A 2015 update. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 412-425.	1.5	132
58	High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. Kidney International, 2015, 88, 386-395.	5.2	84
59	Mitochondrial energetic defects in muscle and brain of aHmbs^{â˜’/â˜’}mouse model of acute intermittent porphyria. Human Molecular Genetics, 2015, 24, 5015-5023.	2.9	34
60	Human Erythroid 5-Aminolevulinate Synthase Mutations Associated with X-Linked Protoporphyria Disrupt the Conformational Equilibrium and Enhance Product Release. Biochemistry, 2015, 54, 5617-5631.	2.5	18
61	LC-MS/MS method for hepcidin-25 measurement in human and mouse serum: clinical and research implications in iron disorders. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1557-67.	2.3	43
62	Assessment of Cardiac Iron Overload in Chonically Transfused Patients with Thalassemia, Sickle Cell Anemia, and Myelodysplastic Syndromes. Blood, 2015, 126, 2151-2151.	1.4	0
63	Antisense Oligonucleotide-Based Therapy in Human Erythropoietic Protoporphyria. American Journal of Human Genetics, 2014, 94, 611-617.	6.2	34
64	Acute intermittent porphyria causes hepatic mitochondrial energetic failure in a mouse model. International Journal of Biochemistry and Cell Biology, 2014, 51, 93-101.	2.8	51
65	Urinary Metabolic Fingerprint of Acute Intermittent Porphyria Analyzed by ¹H NMR Spectroscopy. Analytical Chemistry, 2014, 86, 2166-2174.	6.5	21
66	Pro-oxidant effect of ALA is implicated in mitochondrial dysfunction of HepG2 cells. Biochimie, 2014, 106, 157-166.	2.6	24
67	Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?. EuPA Open Proteomics, 2014, 3, 60-67.	2.5	19
68	Les porphyries hÃ©rÃ©ditaires : anomalies du mÃ©tabolisme de lâ€™hÃ¨me. Bulletin De L'Academie Nationale De Medecine, 2014, 198, 1069-1093.	0.0	0
69	Erythropoietic Protoporphyric Red Blood Cells Are Resistant to the Growth of Malarial Parasites. Blood, 2014, 124, 2670-2670.	1.4	0
70	Epistasis in iron metabolism: complex interactions between Cp, Mon1a, and Slc40a1 loci and tissue iron in mice. Mammalian Genome, 2013, 24, 427-438.	2.2	0
71	PXR-ALAS1: A key regulatory pathway in liver toxicity induced by isoniazid-rifampicin antituberculosis treatment. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 439-441.	1.5	9
72	Hepcidin regulates intrarenal iron handling at the distal nephron. Kidney International, 2013, 84, 756-766.	5.2	58

#	Article	IF	Citations
73	Heme Biosynthesis and Pathophysiology of Porphyrias. Handbook of Porphyrin Science, 2013, , 89-118.	0.8	2
74	Late-Onset X-Linked Dominant Protoporphyria: An Etiology of Photosensitivity in the Elderly. Journal of Investigative Dermatology, 2013, 133, 1688-1690.	0.7	11
75	Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP). Human Molecular Genetics, 2013, 22, 1280-1288.	2.9	39
76	Iron metabolism in patients with anorexia nervosa: elevated serum hepcidin concentrations in the absence of inflammation. American Journal of Clinical Nutrition, 2012, 95, 548-554.	4.7	36
77	ABCB6 is dispensable for erythropoiesis and specifies the new blood group system Langereis. Nature Genetics, 2012, 44, 170-173.	21.4	127
78	A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases. British Journal of Dermatology, 2012, 167, 888-900.	1.5	66
79	Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases. British Journal of Dermatology, 2012, 167, 901-913.	1.5	71
80	Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior. Nature Genetics, 2012, 44, 174-177.	21.4	105
81	An Uncommon Option for Surviving Bariatric Surgery: Regaining Weight!. American Journal of Medicine, 2012, 125, e1-e2.	1.5	7
82	Comprehensive cytochrome P450 CYP1A2 gene analysis in French caucasian patients with familial and sporadic porphyria cutanea tarda. British Journal of Dermatology, 2012, 166, 425-429.	1.5	8
83	Protoporphyrin Retention in Hepatocytes and Kupffer Cells Prevents Sclerosing Cholangitis in Erythropoietic Protoporphyria Mouse Model. Gastroenterology, 2011, 141, 1509-1519.e3.	1.3	39
84	Acute porphyric attack mimicking HIV-associated progressive polyradiculoneuropathy. MÃ©decine Et Maladies Infectieuses, 2011, 41, 441-443.	5.0	1
85	ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. Blood, 2011, 118, 1443-1451.	1.4	80
86	Hepatocellular carcinoma without cirrhosis: think acute hepatic porphyrias and vice versa. Journal of Internal Medicine, 2011, 269, 521-524.	6.0	22
87	Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Human Mutation, 2011, 32, 590-597.	2.5	56
88	Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. Intensive Care Medicine, 2010, 36, 1044-1048.	8.2	79
89	A homoallelic FECH mutation in a patient with both erythropoietic protoporphyria and palmar keratoderma. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1349-1353.	2.4	11
90	Iron Regulatory Proteins Secure Mitochondrial Iron Sufficiency and Function. Cell Metabolism, 2010, 12, 194-201.	16.2	110

#	Article	IF	Citations
91	Porphyrias. Lancet, The, 2010, 375, 924-937.	13.7	644
92	Role of two nutritional hepatic markers (insulinâ€like growth factor 1 and transthyretin) in the clinical assessment and followâ€up of acute intermittent porphyria patients. Journal of Internal Medicine, 2009, 266, 277-285.	6.0	28
93	Erythropoietic protoporphyria. Orphanet Journal of Rare Diseases, 2009, 4, 19.	2.7	178
94	Chediak-Steinbrinck-Higashi Syndrome. , 2009, , 314-314.		0
95	C-Terminal Deletions in the ALAS2 Gene Lead to Gain of Function and Cause X-linked Dominant Protoporphyria without Anemia or Iron Overload. American Journal of Human Genetics, 2008, 83, 408-414.	6.2	246
96	Melatonin and Environmental Lighting Regulate ALAâ€S Gene Expression and So Porphyrin Biosynthesis in the Rat Harderian Gland. Chronobiology International, 2008, 25, 851-867.	2.0	10
97	Sequential regulation of ferroportin expression after erythrophagocytosis in murine macrophages: early mRNA induction by haem, followed by iron-dependent protein expression. Biochemical Journal, 2008, 411, 123-131.	3.7	120
98	Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. Blood, 2007, 109, 811-818.	1.4	58
99	Genetic Study of Variation in Normal Mouse Iron Homeostasis Reveals Ceruloplasmin as an HFE-Hemochromatosis Modifier Gene. Gastroenterology, 2007, 132, 679-686.	1.3	26
100	Contribution of a Common Single-Nucleotide Polymorphism to the Genetic Predisposition for Erythropoietic Protoporphyria. American Journal of Human Genetics, 2006, 78, 2-14.	6.2	164
101	Biochemical compared to molecular diagnosis in acute intermittent porphyria. Journal of Inherited Metabolic Disease, 2006, 29, 157-161.	3.6	4
102	A mouse model provides evidence that genetic background modulates anemia and liver injury in erythropoietic protoporphyria. American Journal of Physiology - Renal Physiology, 2005, 288, G1208-G1216.	3.4	32
103	Mutations in human CPO gene predict clinical expression of either hepatic hereditary coproporphyria or erythropoietic harderoporphyria. Human Molecular Genetics, 2005, 14, 3089-3098.	2.9	44
104	Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea. Biomedicine and Pharmacotherapy, 2005, 59, 20-24.	5.6	52
105	Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases. British Journal of Cancer, 2004, 90, 1230-1234.	6.4	25
106	Modulation of penetrance by the wild-type allele in dominantly inherited erythropoietic protoporphyria and acute hepatic porphyrias. Human Genetics, 2004, 114, 256-262.	3.8	40
107	Analytical correlation between plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in patients presenting with dyspnea. Clinical Biochemistry, 2004, 37, 933-936.	1.9	15
108	Acute Intermittent Porphyria: From Clinical to Molecular Aspects. , 2003, , 23-41.		7

#	Article	IF	Citations
109	P442 N terminal brain natriuretic peptide versus brain natriuretic peptide for the diagnosis of heart failure in patients over 75 years old. European Heart Journal, 2003, 24, 62.	2.2	0
110	Ancestral Founder of Mutation W283X in the Porphobilinogen Deaminase Gene among Acute Intermittent Porphyria Patients. Human Heredity, 2002, 54, 69-81.	0.8	17
111	Human hereditary hepatic porphyrias. Clinica Chimica Acta, 2002, 325, 17-37.	1.1	66
112	The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nature Genetics, 2002, 30, 27-28.	21.4	237
113	A molecular, enzymatic and clinical study in a family with hereditary coproporphyria. Journal of Inherited Metabolic Disease, 2002, 25, 279-286.	3.6	14
114	Hemochromatosis (HFE) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria cutanea tarda (sPCT). Cellular and Molecular Biology, 2002, 48, 33-41.	0.9	11
115	Heme-arginate in the treatment of acute porphyrias : effect on iron metabolism and heme catabolites. Journal of Hepatology, 2001, 34, 197-198.	3.7	0
116	Characterization of Mutations in the CPO Gene in British Patients Demonstrates Absence of Genotype-Phenotype Correlation and Identifies Relationship between Hereditary Coproporphyria and Harderoporphyria. American Journal of Human Genetics, 2001, 68, 1130-1138.	6.2	62
117	Influence of Age and Gender on the Clinical Expression of Acute Intermittent Porphyria Based on Molecular Study of Porphobilinogen Deaminase Gene Among Swiss Patients. Molecular Medicine, 2001, 7, 535-542.	4.4	39
118	Identification of a Prevalent Nonsense Mutation (W283X) and Two Novel Mutations in the Porphobilinogen Deaminase Gene of Swiss Patients with Acute Intermittent Porphyria. Human Heredity, 2000, 50, 247-250.	0.8	23
119	Porphobilinogen deaminase gene in African and Afro-Caribbean ethnic groups: mutations causing acute intermittent porphyria and specific intragenic polymorphisms. Human Genetics, 2000, 107, 150-159.	3.8	18
120	Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. Journal of Hepatology, 2000, 32, 933-939.	3.7	124
121	Inheritance in Erythropoietic Protoporphyria: A Common Wild-Type Ferrochelatase Allelic Variant With Low Expression Accounts for Clinical Manifestation. Blood, 1999, 93, 2105-2110.	1.4	140
122	Heme and acute inflammation. Role in vivo of heme in the hepatic expression of positive acute-phase reactants in rats. FEBS Journal, 1999, 261, 190-196.	0.2	20
123	Variegate Porphyria in Western Europe: Identification of PPOX Gene Mutations in 104 Families, Extent of Allelic Heterogeneity, and Absence of Correlation between Phenotype and Type of Mutation. American Journal of Human Genetics, 1999, 65, 984-994.	6.2	100
124	Evaluation of mutation screening by heteroduplex analysis in acute intermittent porphyria: comparison with denaturing gradient gel electrophoresis. Clinica Chimica Acta, 1999, 279, 133-143.	1.1	16
125	New mutations of the hydroxymethylbilane synthase gene in German patients with acute intermittent porphyria. Molecular and Cellular Probes, 1999, 13, 443-447.	2.1	10
126	Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology, 1998, 27, 848-852.	7.3	49

#	Article	IF	Citations
127	Exon 1 donor splice site mutations in the porphobilinogen deaminase gene in the non-erythroid variant form of acute intermittent porphyria. Human Genetics, 1998, 103, 570-575.	3.8	29
128	Mutations in the Ferrochelatase Gene of Four Spanish Patients with Erythropoietic Protoporphyria. Journal of Investigative Dermatology, 1998, 111, 406-409.	0.7	11
129	Systematic Analysis of Molecular Defects in the Ferrochelatase Gene from Patients with Erythropoietic Protoporphyria. American Journal of Human Genetics, 1998, 62, 1341-1352.	6.2	128
130	Molecular characterization of homozygous variegate porphyria. Human Molecular Genetics, 1998, 7, 1921-1925.	2.9	49
131	Molecular Characterization of Homozygous Variegate Porphyria. Human Molecular Genetics, 1998, 7, 1921-1925.	2.9	37
132	Acute Hepatic Porphyrias and Primary Liver Cancer. New England Journal of Medicine, 1998, 338, 1853-1854.	27.0	33
133	Nitric oxide synthase inhibition and the induction of cytochrome P-450 affect heme oxygenase-1 messenger RNA expression after partial hepatectomy and acute inflammation in rats. Critical Care Medicine, 1998, 26, 1683-1689.	0.9	17
134	Molecular analysis of porphobilinogen (PBG) deaminase gene mutations in acute intermittent porphyria: first study in patients of Slavic origin. Scandinavian Journal of Clinical and Laboratory Investigation, 1997, 57, 217-224.	1.2	17
135	Molecular Epidemiology and Diagnosis of PBG Deaminase Gene Defects in Acute Intermittent Porphyria. American Journal of Human Genetics, 1997, 60, 1373-1383.	6.2	139
136	Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. Journal of Internal Medicine, 1997, 242, 213-217.	6.0	110
137	Three novel mutations in the coproporphyrinogen oxidase gene. Human Mutation, 1997, 9, 78-80.	2.5	20
138	Protoporphyrinogen Oxidase: Complete Genomic Sequence and Polymorphisms in the Human Gene. Biochemical and Biophysical Research Communications, 1996, 226, 226-230.	2.1	36
139	Detection of Four Novel Mutations in the Porphobilinogen Deaminase Gene in French Caucasian Patients with Acute Intermittent Porphyria. Human Heredity, 1996, 46, 177-180.	0.8	14
140	R<scp>eview</scp>: Molecular pathogenesis of hepatic acute porphyrias. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 1046-1052.	2.8	31
141	Mutations in the protoporphyrinogen oxidase gene in patients with variegate porphyria. Human Molecular Genetics, 1996, 5, 407-410.	2.9	54
142	Increased delta aminolevulinic acid and decreased pineal melatonin production. A common event in acute porphyria studies in the rat.. Journal of Clinical Investigation, 1996, 97, 104-110.	8.2	40
143	Porphobilinogen deaminase gene structure and molecular defects. Journal of Bioenergetics and Biomembranes, 1995, 27, 197-205.	2.3	33
144	Molecular abnormalities of coproporphyrinogen oxidase in patients with hereditary coproporphyria. Journal of Bioenergetics and Biomembranes, 1995, 27, 215-219.	2.3	19

#	Article	IF	Citations
145	Variegate porphyria: diagnostic value of fluorometric scanning of plasma porphyrins. Clinica Chimica Acta, 1995, 238, 163-168.	1.1	56
146	Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks. Life Sciences, 1993, 53, 621-627.	4.3	52
147	Thyroid hormone extraction by plasma exchange: a study of extraction rate. Biomedicine and Pharmacotherapy, 1992, 46, 413-417.	5.6	7
148	Immunological specificity of monoclonal antibodies to Chlamydia psittaci ovine abortion strain. Immunology Letters, 1990, 23, 217-221.	2.5	2